


***Corresponding author:**

Dong-Kun Yang
Viral Disease Division, Animal and Plant
Quarantine Agency, Ministry of Agriculture,
Food and Rural Affairs (MAFRA), 177
Hyeoksins 8-ro, Gimcheon 39660, Korea
Tel: +82-54-912-0785
Fax: +82-54-912-0182
E-mail: yangdk@korea.kr

ORCID:
<https://orcid.org/0000-0001-5765-3043>

Conflict of interest:
The authors declare no conflict of interest.

Received: Jun 15, 2022
Revised: Aug 16, 2022
Accepted: Aug 31, 2022



© 2022 The Korean Society of Veterinary Science.
© This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial license (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Incidence and sero-surveillance of feline viruses in Korean cats residing in Gyeonggi-do

Dong-Kun Yang^{1,*}, Yu-Ri Park¹, Eun-ju Kim¹, Hye Jeong Lee¹, Kyu-Sik Shin¹, Ju-Hun Kim², Kyunghyun Lee¹, Bang-Hun Hyun¹

¹Viral Disease Division, Animal and Plant Quarantine Agency, Ministry of Agriculture, Food and Rural Affairs (MAFRA), Gimcheon 39660, Korea

²Komipharm, Siheung 15094, Korea

Abstract

Incidences of major feline viral diseases provide basic information for preventing viral disease in cats. Despite the growing interest in feline viral diseases, sero-surveillances have been lacking. In this study, we analyzed the diagnoses of feline viral diseases and conducted a sero surveillance of feline panleukopenia virus (FPV), feline calicivirus (FCV), feline herpesvirus-1 (FHV-1), and feline infectious peritonitis virus (FIPV) in Korean cats. Of the 204 confirmed cases since 2015, the numbers of diagnoses for FPV, FIPV, FCV, feline influenza virus, and FHV-1 were 156, 32, 12, 3, and 1 case, respectively. In total, 200 sera, collected between 2019 and 2021, were screened for the presence of antibodies against FPV, 2 FCVs, FHV-1, and FIPV using a hemagglutination inhibition test and a virus-neutralizing assay (VNA). The overall seropositive rates in cats tested for FPV, the 2 FCVs, FHV-1, and FIPV were 92.5%, 42.0%, 37.0%, 52.0%, and 14.0%, respectively. A low correlation ($r = 0.466$) was detected between the VNA titers of 2 FCV strains. The highest incidence and seropositive rate of FPV reveal that FPV is circulating in Korean cats. The low r -value between 2 FCVs suggests that a new feline vaccine containing the 2 kinds of FCVs is required.

Keywords: incidence; serology; feline panleukopenia virus; feline infectious peritonitis virus

Introduction

Feline panleukopenia virus (FPV), feline calicivirus (FCV), feline herpesvirus-1 (FHV-1), and feline coronavirus (FCoV) are major infectious pathogens in cats worldwide [1-4]. FPV (family *Parvoviridae*) is highly related to canine parvovirus type 2, with 98% or more homology [5]. FPV transmitted via the oronasal and fecal routes has been reported in Felidae and wild animals [6]. The clinical symptoms of FPV infection in cats include high fever, anorexia, vomiting, and hemorrhagic diarrhea resulting in death in about 50% of infected kittens [7]. FPV is very stable in the environment and causes persistent infection. The FPV VP2 protein induces neutralizing antibodies and has been used to detect FPV antibodies after natural infections and vaccination [8].

FCV (genus *Vesivirus*, family *Caliciviridae*) is a highly adaptable RNA virus that evolves rapidly under harsh environmental pressure [2]. FCV is transmitted via the oronasal route, and ocular discharge from infected cats is highly contagious to

other cats. FCV infection manifests in 2 forms in cats < 1 year of age. The clinical signs known as the classic form are fever, nasal and ocular discharge, oral ulcerations, and conjunctivitis. The clinical symptoms known as virulent systemic disease are pyrexia, cutaneous edema, ulcerative dermatitis, anorexia, and jaundice with sudden death [2,9]. The VP1 protein containing the major B cell epitopes acts as a target for inducing the neutralizing antibody against FCV [10].

FHV-1 (genus *Varicellovirus*, subfamily Alphaherpesvirinae, family *Herpesviridae*) consists of approximately 135 kbp and causes feline viral rhinotracheitis. FHV-1 is transmitted through contact with a recently infected cat via the oronasal route [11]. Cats infected with FHV-1 develop fever, nasal discharge, conjunctivitis, keratitis, and pneumonia, and may die [12]. Infection of the trigeminal ganglion by FHV-1 leads to a latent infection and clinical signs can be reactivated by high stress or immunosuppression, resulting in infectious virus shedding [13]. Glycoproteins known as gB, gC, and gD play a key role in the induction of the humoral and cell-mediated immune responses [14].

FCoV (family *Coronaviridae*) has different antigenic relevance to canine coronavirus. Based on a serological and molecular analysis, FCoV is classified into 2 biotypes called feline enteric coronavirus (FECV) and feline infectious peritonitis virus (FIPV) [4]. FECV infection shows mild or subclinical enteric symptoms, but cats infected with FIPV develop clinical signs, such as lethargy, decreased appetite, weight loss, and eventually death [15]. FIPV is transmitted from infected cats via the fecal or oral route.

Methods such as virus neutralization (VN), hemagglutination inhibition (HI), enzyme-linked immunosorbent assays, and one-step immune chromatography assays are used to detect antibodies against FPV, FCV, FHV-1, and FIPV [16,17]. Among these serological methods, the HI test to detect FPV antibodies has been used as a standard method, and the VN test has been used to measure antibodies against FCV, FHV-1, and FIPV. Although FPV, FCV, FHV-1, and FIPV infections have been reported in South Korean cats [17–20], a recent incidence and serologic investigations of major feline pathogens are lacking. In this study, we analyzed the incidence of feline viral diseases since 2015. Serological investigations of FPV, the 2 FCVs, FHV-1, and FIPV were performed using 200 cat sera collected between 2019 and 2021.

Materials and Methods

Cells and viruses

CRFK (CCL-94; ATCC, USA) cells were grown in Dulbecco's

modified Eagle medium supplemented with 10% (v/v) heat-inactivated fetal bovine serum and an antibiotic-antimycotic solution (Gibco, USA). The cells were used to propagate FPV, the 2 FCVs, FHV-1, and FIPV, and for the virus neutralization assay (VNA). The FPV1901, FCV17D03, FCV17D283, and FHV191071 strains were isolated from naturally infected Korean cats in 2017 and 2019, respectively [17–19]. The FIPV strain was obtained from a commercial live FIPV vaccine.

Blood sampling

A total of 200 blood samples were collected for the sero-surveillance study from cats residing in Gyeonggi Province, South Korea from 2019 to 2021. The age of cats varied from 0.5 to 10 years. Among the cat breeds, Korean domestic short hair was the most common. No information was available about whether the cats had been inoculated with vaccines. Blood samples were subjected to centrifugation and the sera were stored at -20°C until use.

HA and HI tests

The HA test was performed by preparing serial 2-fold dilutions of the FPV strain in 50 µL of Sorensen buffer (pH 6.0) with 50 µL of 0.6% pig erythrocytes. The HA titer was expressed as the reciprocal of the highest dilution of FPV that hemagglutinated. The HI test of the FPV1901 strain was performed in a 96-well microplate as described previously [1], with slight modifications. Briefly, 50 µL of serum were treated with 25% kaolin and packed pig erythrocytes to remove non-specific inhibitors. Eight HA units of FPV1901 in 25 µL were added to 25 µL of the treated serum for the HI test. After 1 hour of incubation at 37°C, 50 µL of 0.6% pig erythrocytes were added, and the microplates were incubated at 4°C for 1 hour. The HI titer of the cat serum was expressed as the reciprocal of the highest dilution of serum showing complete inhibition of hemagglutination. Serum samples with HI titers ≥ 1:20 were considered positive [21].

Virus neutralization assay

The VNA for FCV17D03, FCV17D283, FHV191071, and FIPV was carried out in 96-well plates using cat sera inactivated at 56°C for 30 min. Fifty microliters of 2-fold serially diluted serum were mixed with an equal volume of FCV17D03, FCV17D283, FHV191071, or FIPV containing 200 TCID₅₀/0.1 mL. After incubating the mixture at 37°C for 1 hour, 100 µL of a CRFK cell suspension containing 2 × 10⁴ cells were added to each well. The plates were incubated for 3 to 4 days in a humidified incubator with 5% CO₂. Each well was examined under a microscope to detect virus-specific cytopathic effects (CPEs).

The VNA titers were expressed as the reciprocal of the highest serum dilution showing complete inhibition of the CPEs. A VNA titer $\geq 1:2$ was considered positive against FCV17D03, FCV17D283, FHV191071, and FIPV.

Statistical analysis

Least-squares linear regression analysis was employed to determine the correlation coefficients (*r* values) between the VNA titers of the 2 FCV strains. The *r* values were automatically calculated in Microsoft Excel 2010 software (Microsoft Corp., USA). A *p*-value < 0.05 was considered significant.

Results

Feline viral pathogens, including FPV, FCV, FHV-1, feline influenza virus (FinV), and FIPV, were investigated using data from the Animal and Plant Quarantine Agency (APQA) in South Korea from 2015 to 2021. As shown in Fig. 1, of the 204




Fig. 1. Numbers of feline viral infections confirmed by the Animal and Plant Quarantine Agency from 2015 to 2021 (www.kahis.go.kr). A total of 468 samples were received, and 204 cases were diagnosed with a viral infection. FPV, feline panleukopenia virus; FIPV, feline infectious peritonitis virus; FCV, feline calicivirus; FinV, feline influenza virus; FHV-1, feline herpesvirus-1.

confirmed cases, the largest number of diagnoses was confirmed as FPV (156 cases). The numbers of diagnoses for FIPV, FCV, FinV, and FHV-1 were 32, 12, 3, and 1 case, respectively. No infections of the feline leukemia virus and feline immunodeficiency virus were diagnosed.

The seroprevalence rates of FPV, the 2 FCVs, FHV-1, and FIPV using the HI and VNA results were examined in 200 cat sera collected from Gyeonggi Province South Korea. Of the 200 cats tested in this study, 109 were males and 91 were females. The mean age of the cats was 2.4 years. The overall seropositive rates for FPV, FCV17D03, FCV17D283, FHV-1, and FIPV were 92.5% (185/200), 42.0% (84/200), 37.0% (74/200), 52.0% (104/200), and 13.5% (27/200), respectively (Table 1). No significant differences in the seropositive rates were observed according to year or gender in the 5 viruses.

An HI titer $\geq 1:20$ and a VNA titer $\geq 1:2$ were considered to be seropositive against FPV, FCV17D03, FCV17D283, FHV-1, and FIPV. About 64.5% (129/200) of the HI titers against FPV were $> 1:80$, indicating a protective antibody titer. The most frequent HI titer was 1:160 (17.5%). The most frequent VNA titers against the 2 FCVs and FHV-1 were 1:2 (13.5% and 12.0%) and 1:4 (11.0%), respectively (Fig. 2). No significant differences in the seropositive rates for FPV were detected in the distribution of the HI titers according to age. However, cats > 7 years of age had the highest seropositive rates (65.2% and 30.4%) for FCV17D03 and FIPV. Five-year-old cats had the highest seropositive rate (83.3%) against FHV-1 (Fig. 3).

Figure 4 shows the regression lines and correlation coefficients (*r*) between the VNA titers and the 2 FCV strains. The *r*-value was 0.466, indicating a significant difference between the VNA titers of the FCV17D03 and FCV17D283 strains.

Discussion

A total of 468 cat samples have been sent to the APQA for di-

Table 1. Seropositive rates of FPV, FCV, FHV-1, and FIPV using hemagglutination inhibition and virus neutralization assays in feline blood samples collected from Gyeonggi Province, South Korea

Year/sex	Seropositive rates against 5 feline viral pathogens				
	FPV	FCV17D03	FCV17D283	FHV-1	FIPV
2019	50/55 (90.9)	18/55 (32.7)	18/55 (32.7)	32/55 (58.2)	7/55 (12.7)
2020	69/73 (94.5)	32/73 (43.8)	24/73 (32.9)	27/73 (37.0)	11/73 (15.1)
2021	66/72 (91.7)	34/72 (47.2)	32/77 (41.6)	46/72 (63.9)	10/72 (13.9)
Male	104/109 (95.4)	49/109 (45.0)	41/109 (37.6)	54/109 (49.5)	15/109 (13.8)
Female	81/91 (89.0)	35/91 (38.5)	33/91 (36.3)	50/91 (54.9)	12/91 (13.2)
Total	185/200 (92.5)	84/200 (42.0)	74/200 (37.0)	104/200 (52.0)	28/200 (14.0)

Values are presented as number positive/number tested (% positive).

FPV, feline panleukopenia virus; FCV, feline calicivirus; FHV-1, feline herpesvirus-1; FIPV, feline infectious peritonitis virus.




Fig. 2. Distributions of hemagglutination inhibition (HI) titers and virus neutralization (VN) titers against (A) feline panleukopenia virus (FPV), (B) feline calicivirus (FCV), (C) feline herpesvirus-1 (FHV-1), and (D) feline infectious peritonitis virus (FIPV) in 200 cat sera. An HI titer of 1:20 and a VN titer of 1:2 or higher were considered seropositive against the 5 feline viral pathogens.




Fig. 3. Seropositive rates of the hemagglutination inhibition (HI) titers and virus neutralization (VN) titers against (A) feline panleukopenia virus (FPV), (B) feline calicivirus (FCV), (C) feline herpesvirus-1 (FHV-1), and (D) feline infectious peritonitis virus (FIPV) according to age. Cats of all ages had a high seropositive rate for FPV.




Fig. 4. Correlation (A) of feline calicivirus neutralizing antibody titers in 200 cat sera using the FCV17D03 and FCV17D283 strains, and a comparison (B) of the VN titers between the 2 FCVs. VN, virus neutralization; FCV, feline calicivirus.

agnosis since 2015, and 204 cases were confirmed by histopathological and molecular methods. In our study, 76.4% (156/204) of cats diagnosed at the APQA were confirmed to have FPV, indicating that FPV is the most lethal pathogen causing death in Korean cats. Second, 15.7% (32/204) of the cats were diagnosed with FIPV, which is fatal [15]. Infections of FCV, FinV, and FHV-1 were also identified, and these diseases have been reported worldwide [2,3,22]. Diagnostic information reveals which viral pathogens are circulating in the cat population and provides basic data for prevention.

Sero-surveillance has been used as part of disease management for animal populations. Data obtained through serologic surveys of FPV, FCV, FHV-1, and FIPV help to understand the immune or infectious status in the cat population. In addition, these data provide a basis for recommending vaccination to prevent FPV, FCV, FHV-1, and FIPV. Our seroprevalence results suggest that recommending vaccinations for stray cats is a possible solution [23].

FPV infection has been reported in many countries, and the seroprevalence of FPV has been estimated to range from 28.0% to 83.9% depending on the country and time [23,24]. Anti-FCV, FHV-1, and FIPV antibodies have also been reported in many countries but their levels are highly variable depending on the age and vaccination status of the cats [23–25]. Our serosurvey revealed that the overall seropositive rates against FPV, FCV17D03, FCV17D283, FHV-1, and FIPV were very high (92.5%) for FPV and moderately low (13.5%) for FIPV.

The high FPV seropositive rate suggests that Korean cats are continuously exposed to FPV in the field. Analysis of serum antibody levels helps to determine whether cats can protect themselves against re-exposure to a specific pathogen. It has been reported that dogs with HI titers $\geq 1:80$ are protected against a

canine parvovirus challenge [26]. Therefore, we set and analyzed an HI titer of $\geq 1:80$ as a protective antibody titer. Our study showed that 64.5% of the cats tested had HI titers $\geq 1:80$, indicating that 35.5% of the cats are not protected against wild FPV infection and require vaccination.

In our study, serum antibodies were measured using the 2 FCVs and FHV-1 isolated from Korean cats because of the high genetic variation in FCV [27]. As FCV and FHV-1 are involved in humoral and cellular immunity, it is difficult to judge protection using the VNA titer alone. However, one way to determine whether a cat has been exposed to FCV or FHV-1 is to measure the VNA titer. Our seropositive rates for the 2 FCVs, FHV-1, and FIPV were 42%, 37%, 52%, and 14%, respectively, which are similar to or lower than those reported in other countries [23,24]. Therefore, vaccination is recommended to protect cats from FCV and FHV-1 infection. FIPV has been accepted as an FCoV variant due to specific gene mutations [4]. Cats infected with FIPV and showing clinical symptoms usually die. Therefore, the FIPV antibody titer present in the cat's serum is considered to be a sign of exposure to FIPV or a response to vaccination.

The cross-neutralization test has been used to demonstrate serological differences between mutated viruses or to evaluate the potency of a vaccine against a variant strain [28]. FCV has been divided into at least 2 genogroups based on the VP1 sequence [29]. In this study, the correlation value of the VNA performed using 2 FCVs with 84.8% genetic homology was 0.466, indicating that genetic diversity and serological differences may exist in FCV. Therefore, cats should be inoculated with an FCV vaccine containing at least 2 variants.

In conclusion, major feline viral diseases were investigated in South Korea. The most frequently detected virus in cats was

FPV, followed by FIPV, FCV, FinV, and FHV-1. The overall seropositive rates in cats tested for FPV, FCV17D03, FCV19D283, FHV-1, and FIPV were 92.5%, 42.0%, 37.0%, 52.0%, and 14.0%, respectively, indicating that FPV causes persistent circulating infection in the Korean cat population. The serological correlation for the 2 FCV strains was moderately low ($r = 0.466$), suggesting that there are 2 FCV serotypes. The data presented in this study indicate that FPV is the most life-threatening pathogen in feline viral diseases, and has a high seropositive rate and there are 2 serotypes for FCV. Thus, more sophisticated vaccine program for cats should be considered. Additional studies on the efficacy of FPV vaccine are needed. Moreover, a new FCV vaccine should contain 2 types of FCV strains.

Acknowledgments

This study was supported financially by a grant (B-1543083-2019-21-01) from the Animal and Plant Quarantine Agency, Ministry of Agriculture, Food and Rural Affairs (MAFRA), Republic of Korea.

ORCID

Dong-Kun Yang, <https://orcid.org/0000-0001-5765-3043>
 Yu-Ri Park, <https://orcid.org/0000-0002-2829-4368>
 Eun-ju Kim, <https://orcid.org/0000-0003-1601-6333>
 Hye Jeong Lee, <https://orcid.org/0000-0003-2044-6176>
 Kyu-Sik Shin, <https://orcid.org/0000-0001-6330-2274>
 Ju-Hun Kim, <https://orcid.org/0000-0002-1283-2790>
 Kyunghyun Lee, <https://orcid.org/0000-0002-3113-2781>
 Bang-Hun Hyun, <https://orcid.org/0000-0002-3429-3425>

References

1. Stuetzer B, Hartmann K. Feline parvovirus infection and associated diseases. *Vet J* 2014;201:150–155.
2. Radford AD, Coyne KP, Dawson S, Porter CJ, Gaskell RM. Feline calicivirus. *Vet Res* 2007;38:319–335.
3. Gaskell R, Dawson S, Radford A, Thiry E. Feline herpesvirus. *Vet Res* 2007;38:337–354.
4. Delaplace M, Huet H, Gambino A, Le Poder S. Feline coronavirus antivirals: a review. *Pathogens* 2021;10:1150.
5. Inthong N, Sutacha K, Kaewmongkol S, Sinsiri R, Sribuarod K, Sirinarumitr K, Sirinarumitr T. Feline panleukopenia virus as the cause of diarrhea in a banded linsang (*Prionodon linsang*) in Thailand. *J Vet Med Sci* 2019;81:1763–1768.
6. Chung HC, Kim SJ, Nguyen VG, Shin S, Kim JY, Lim SK, Park YH, Park B. New genotype classification and molecular characterization of canine and feline parvoviruses. *J Vet Sci* 2020;21:e43.
7. Parrish CR. Pathogenesis of feline panleukopenia virus and canine parvovirus. *Baillieres Clin Haematol* 1995;8:57–71.
8. Horiuchi M, Yamaguchi Y, Gojobori T, Mochizuki M, Nagasawa H, Toyoda Y, Ishiguro N, Shinagawa M. Differences in the evolutionary pattern of feline panleukopenia virus and canine parvovirus. *Virology* 1998;249:440–452.
9. Coyne KP, Jones BR, Kipar A, Chantrey J, Porter CJ, Barber PJ, Dawson S, Gaskell RM, Radford AD. Lethal outbreak of disease associated with feline calicivirus infection in cats. *Vet Rec* 2006;158:544–550.
10. Brunet S, Sigoillot-Claude C, Pialot D, Poulet H. Multiple correspondence analysis on amino acid properties within the variable region of the capsid protein shows differences between classical and virulent systemic feline calicivirus strains. *Viruses* 2019;11:1090.
11. Gould D. Feline herpesvirus-1: ocular manifestations, diagnosis and treatment options. *J Feline Med Surg* 2011;13:333–346.
12. Lee Y, Maes R, Tai SS, Soboll Hussey G. Viral replication and innate immunity of feline herpesvirus-1 virulence-associated genes in feline respiratory epithelial cells. *Virus Res* 2019;264:56–67.
13. Maes R. Felid herpesvirus type 1 infection in cats: a natural host model for alphaherpesvirus pathogenesis. *ISRN Vet Sci* 2012;2012:495830.
14. Spatz SJ, Maes RK. Immunological characterization of the feline herpesvirus-1 glycoprotein B and analysis of its deduced amino acid sequence. *Virology* 1993;197:125–136.
15. Felten S, Hartmann K. Diagnosis of feline infectious peritonitis: a review of the current literature. *Viruses* 2019;11:1068.
16. Lappin MR, Andrews J, Simpson D, Jensen WA. Use of serologic tests to predict resistance to feline herpesvirus 1, feline calicivirus, and feline parvovirus infection in cats. *J Am Vet Med Assoc* 2002;220:38–42.
17. Yang DK, Park YR, Park Y, An S, Choi SS, Park J, Hyun BH. Isolation and molecular characterization of feline panleukopenia viruses from Korean cats. *Korean J Vet Res* 2022;62:e10.
18. Yang DK, Park YR, Yoo JY, Choi SS, Park Y, An S, Park J, Kim HJ, Kim J, Kim HH, Hyun BH. Biological and molecular characterization of feline caliciviruses isolated from cats in South Korea. *Korean J Vet Res* 2020;60:195–202.
19. Yang DK, Kim HH, Park YR, Yoo JY, Choi SS, Park Y, An S, Park J, Kim J, Kim HJ, Lee J, Hyun BH. Isolation and molecular characterization of feline herpesvirus 1 from naturally in-

- ected Korean cats. *J Bacteriol Virol* 2020;50:263–272.
20. An DJ, Jeoung HY, Jeong W, Park JY, Lee MH, Park BK. Prevalence of Korean cats with natural feline coronavirus infections. *Virol J* 2011;8:455.
 21. Yang DK, Yoon SS, Byun JW, Lee KW, Oh YI, Song JY. Serological survey for canine parvovirus type 2a (CPV-2a) in the stray dogs in South Korea. *J Bacteriol Virol* 2010;40:77–81.
 22. Harder TC, Vahlenkamp TW. Influenza virus infections in dogs and cats. *Vet Immunol Immunopathol* 2010;134:54–60.
 23. Dall'Ara P, Labriola C, Sala E, Spada E, Magistrelli S, Lauzi S. Prevalence of serum antibody titres against feline panleukopenia, herpesvirus and calicivirus infections in stray cats of Milan, Italy. *Prev Vet Med* 2019;167:32–38.
 24. Digangi BA, Gray LK, Levy JK, Dubovi EJ, Tucker SJ. Detection of protective antibody titers against feline panleukopenia virus, feline herpesvirus-1, and feline calicivirus in shelter cats using a point-of-care ELISA. *J Feline Med Surg* 2011;13:912–918.
 25. Liu C, Liu Y, Qian P, Cao Y, Wang J, Sun C, Huang B, Cui N, Huo N, Wu H, Wang L, Xi X, Tian K. Molecular and serological investigation of cat viral infectious diseases in China from 2016 to 2019. *Transbound Emerg Dis* 2020;67:2329–2335.
 26. Pollock RV, Carmichael LE. Dog response to inactivated canine parvovirus and feline panleukopenia virus vaccines. *Cornell Vet* 1982;72:16–35.
 27. Zheng M, Li Z, Fu X, Lv Q, Yang Y, Shi F. Prevalence of feline calicivirus and the distribution of serum neutralizing antibody against isolate strains in cats of Hangzhou, China. *J Vet Sci* 2021;22:e73.
 28. Porter CJ, Radford AD, Gaskell RM, Ryvar R, Coyne KP, Pinchbeck GL, Dawson S. Comparison of the ability of feline calicivirus (FCV) vaccines to neutralise a panel of current UK FCV isolates. *J Feline Med Surg* 2008;10:32–40.
 29. Zhou L, Fu N, Ding L, Li Y, Huang J, Sha X, Zhou Q, Song X, Zhang B. Molecular characterization and cross-reactivity of feline calicivirus circulating in Southwestern China. *Viruses* 2021;13:1812.